Skip to main navigation Skip to search Skip to main content

A randomised controlled trial assessing the efficacy of an electronic discharge communication tool for preventing death or hospital readmission

  • Maria J. Santana*
  • , Jayna Holroyd-Leduc
  • , Danielle A. Southern
  • , Ward W. Flemons
  • , Maeve O'Beirne
  • , Michael D. Hill
  • , Alan J. Forster
  • , Deborah E. White
  • , William A. Ghali
  • *Corresponding author for this work
  • University of Calgary
  • University of Ottawa

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

Objective To assess the efficacy of an electronic discharge communication tool (e-DCT) for preventing death or hospital readmission, as well as reducing patient-reported adverse events after hospital discharge. The e-DCT assessed has already been shown to yield high-quality discharge summaries with high levels of patient and physician satisfaction. Methods This two-arm randomised controlled trial was conducted in a Canadian tertiary care centre's internal medicine medical teaching units. Out of the 1953 patients approached and screened for inclusion, 1399 were randomised and available for data linkage for determination of the primary outcome. Participants were randomly assigned to e-DCT versus usual care (traditional discharge communication generated by dictation). The primary outcome was a composite of death or readmission within 90 days. The secondary outcome included any patient-reported adverse events within 30 days of discharge. Results Among 1399 randomised participants, 230 of 701 participants (32.8%) in the e-DCT group experienced the primary composite outcome of death or readmission within 90 days vs 205 of 698 participants (29.4%) in the usual care group (p=0.166). The incidence at 30 days of patient-reported adverse outcomes (35% for e-DCT vs 34% for usual care) and adverse events (2.1% for e-DCT vs 1.8% for usual care) also did not differ significantly between groups. Conclusions The e-DCT tested did not reduce the composite endpoint of death or readmission at 90 days, nor the incidence of patient-reported adverse events at 30 days. This neutral finding for hard clinical endpoints needs to be considered in the context of high patient and physician satisfaction, and high quality of discharge summaries.

Original languageEnglish
Pages (from-to)993-1003
Number of pages11
JournalBMJ Quality and Safety
Volume26
Issue number12
DOIs
StatePublished - 1 Dec 2017
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'A randomised controlled trial assessing the efficacy of an electronic discharge communication tool for preventing death or hospital readmission'. Together they form a unique fingerprint.

Cite this